Among pandemic-era stocks, Moderna ($Moderna, Inc.(MRNA)$ ) may undoubtedly be one of the most extraordinary. Since 2020, the Cambridge, Massachusetts-based COVID-19 vaccine producer gained 680%, an impressive rally for its shares which vastly outperformed the competition. However, since the start of 2022, the biotech company's stock has tumbled more than 42% amid the broad market selloff in growth equities and signs that governments might be moving to end pandemic restrictions. Moderna closed Tuesday at $144.97. Moderna Weekly Chart Earlier, Britain announced it planned to end pandemic restrictions, becoming the first major Western government to do so. People with COVID-19 will no longer have to self-isolate from Thursday, while access to free tests

Market forces rained on the parade ofLucid Group, Inc.($Lucid Group Inc(LCID)$ ) shareholders, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) estimates were cut sharply as the analysts factored in the latest outlook for the business, concluding that they were too optimistic previously. After the downgrade, the six analysts covering Lucid Group are now predicting revenues of US$1.3b in 2022. If met, this would reflect a substantial improvement in sales compared to the last 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 57% to US$1.23. However, before this estimates update, the consensus had been expecting revenues of US$2.0b and US$1.12 per share in lo